Related Experiment Video
Updated: Aug 9, 2025
09:55
Generation and Quantitative Characterization of Functional and Polarized Biliary Epithelial Cysts
Published on: May 16, 2020
3.9K
Prognostic modeling in biliary diseases
Camelia Ciobanu1, Mark W Russo
1Division of Hepatology, Atrium Health Wake Forest Baptist, Wake Forest University School of Medicine, Charlotte, North Carolina, USA.
Current Opinion in Gastroenterology
|February 23, 2023
Summary
New prognostic models for primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC) offer improved predictions for patient outcomes. These tools aid in clinical trial design and patient risk assessment.
Area of Science:
- Hepatology
- Internal Medicine
- Clinical Trials
Background:
- Cholestatic liver diseases, including primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), require accurate prognostic tools.
- Existing models like alkaline phosphatase and Mayo Risk Score have limitations in predicting key clinical events.
Approach:
- Review of noninvasive prognostic models for PSC and PBC.
- Evaluation of models incorporating clinical data, imaging (elastography, MRI), and biochemical markers.
- Comparison of model performance against established scores.
Key Points:
- Advanced noninvasive models outperform traditional scores for predicting transplant-free survival and hepatic decompensation in PSC and PBC.
- Specific PSC models include UK-PSC, PSC Risk Estimate Tool, and Amsterdam Oxford.
- PBC models include UK-PBC, GLOBE score, and Paris II score.
- Integration of elastography and MRI findings enhances prognostic accuracy.
Conclusions:
- Noninvasive prognostic models provide valuable insights into patient risk for cholestatic diseases.
- These models can serve as surrogate endpoints in clinical trials evaluating new therapeutic agents.
